Compare Twist Bioscience Corp (TWST) vs Zoom Video Communications, Inc. (ZM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Zoom Video Communications, Inc. — how do they compare? Twist Bioscience Corp trades at $163.28 (market cap $10.08B), while Zoom Video Communications, Inc. trades at $95.93 (market cap $27.62B). The key difference: Zoom Video Communications, Inc. is far larger — about 2.7× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Zoom Video Communications, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Twist Bioscience Corp for 27 Days and Zoom Video Communications, Inc. for 92 Days on average.
| TWST | ZM | |
|---|---|---|
Market Cap | $10.08B | $27.62B |
Volume | 4,229,037 | 3,913,188 |
Sector | Health | Technology |
52-Week High | $205.00 | $111.88 |
52-Week Low | $25.45 | $72.72 |
Typical Hold Time | 27 Days | 92 Days |
Enterprise Value | $10.01B | $20.43B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Zoom Communications (ZM) trades at $96.20, up 1.51% today, with a bullish technical signal from moving averages and a consensus analyst price target of $118.08. The company reported strong earnings beats in Q1 and Q2 2026, with net income reaching $1.01 billion in 2025 and a robust net income margin of 65.19%. Recent news highlights AI-driven product launches and board appointments, signaling strategic growth initiatives.
The outlook for ZM is positive, supported by solid profitability and Wall Street's buy ratings, but risks include competitive pressures and reliance on international sales. The stock's current valuation metrics, such as a P/E of 8.79, suggest potential upside if earnings growth continues, though investors should monitor execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Zoom Video Communications, Inc.
Zoom Video Communications, Inc. develops a people-centric cloud service that transforms real-time collaboration experience. The Company offers unified meeting experience, a cloud service that provides a 3-in-1 meeting platform with HD video conferencing, mobility, and web meetings. Zoom Video Communications serves customers worldwide.
Read more on ZM →
